CDKN2A and cancer: In contrast, carcinoma development was significantly increased in Vil-Cre;BrafLSL-V637E/+;p16Ink4∗ mice, which had on average 6.4 times as many cancers as Vil-Cre;BrafLSL-V637E/+;p16Ink4a+/+ mice (p < 0.001; Figure 4C; Table S5).